New hope for kids with tough liver cancer: immunotherapy trial opens

NCT ID NCT04134559

First seen Mar 04, 2026 · Last updated May 06, 2026 · Updated 10 times

Summary

This study tests the drug pembrolizumab (Keytruda) in children and young adults up to age 30 whose liver cancer has come back or not responded to treatment. The goal is to see if the drug can shrink tumors or slow the disease. About 18 participants will receive the immunotherapy, and researchers will also study how the immune system responds.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Baylor College of Medicine

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Children's Hospital Boston

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact

    Contact

  • Cincinnati Children's Medical Center

    RECRUITING

    Cincinnati, Ohio, 45229, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-••••

    Contact

  • University of California San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.